Sichuan Kelun Pharmaceutical Co., Ltd. Class A
002422
Rang in Aktien
#2008
Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and... Sichuan Kelun Pharmaceutical Co., Ltd. researches, develops, produces, and sells infusion and non-infusion pharmaceutical products in China and internationally. The company operates through Chuanning, Botai, and Other Business segments. The company offers infusion products; oral medication and other dosage form; medical devices, such as infusion sets, sterile dispensing and injection syringes, vein detained needles, nebulizer sets, and vacuum blood collection tubes; over-the-counter products; and APIs to treat cardiovascular, IPF, ED, anti-tumor, anti-emetic, antibiotic, VB12, anti-rheumatoid arthritis, multiple sclerosis, anti-schizophrenia, CKD and anti-anemia, polypeptide, and other indications. It also provides ambroxol hydrochloride, potassium chloride, sodium chloride, magnesium sulfate, glucose, sterile water, sodium bicarbonate, lidocaine hydrochloride, vitamin B6, ribavirin, ceftazidime, 5% glucose, and ceftriaxone sodium injections. In addition, the company engages in investment; import and export; enterprise management; logistics and transportation; business services; agricultural non-staple food processing; production and sale of pharmaceutical intermediates; research and development of bio-based materials technology; Internet and related services; crop planting; professional technical; biotechnology extension; socio-economic consultation; technology promotion; medical research and testing exhibition; general cargo road transport; ecological protection and environmental management; and wholesale and retail. It exports its products to Japan. The company was formerly known as Sichuan Kelun Pharmaceutical Factory Co., Ltd and changed its name to Sichuan Kelun Pharmaceutical Co., Ltd. in August 2003. The company was founded in 1996 and is based in Chengdu, the People's Republic of China. Sichuan Kelun Pharmaceutical Co., Ltd. operates as a subsidiary of Sichuan Kelun Industry Group CO., LTD.
Aktienkurs
$6.40
Marktkapitalisierung
$10.19B
Veränderung (1 Tag)
-0.77%
Veränderung (1 Jahr)
27.14%
Land
CN
Handel Sichuan Kelun Pharmaceutical Co., Ltd. Class A (002422)
Kategorie
Healthcare
Gewinn für Sichuan Kelun Pharmaceutical Co., Ltd. Class A (002422)
Gewinn im Jun 2026 TTM: $380.26M
Laut den aktuellen Finanzberichten von Sichuan Kelun Pharmaceutical Co., Ltd. Class A betragen die aktuellen Gewinne des Unternehmens $380.26M. Im Jahr 2024 erzielte das Unternehmen einen Gewinn von $587.11M, eine Steigerung gegenüber dem Gewinn im Jahr 2023, der $505.81M betrug. Die auf dieser Seite angezeigten Gewinne sind die Gewinne vor Zinsen und Steuern, auch bekannt als EBIT.
Gewinnverlauf von Sichuan Kelun Pharmaceutical Co., Ltd. Class A von 2007 bis 2026
Gewinn am Ende jedes Jahres
| Jahr | Gewinn | ändert |
|---|---|---|
| 2026 (TTM) | $380.26M | 10.67% |
| 2025 | $343.58M | -41.48% |
| 2024 | $587.11M | 16.07% |
| 2023 | $505.81M | 68.72% |
| 2022 | $299.79M | 61.80% |
| 2021 | $185.28M | 26.74% |
| 2020 | $146.19M | -18.97% |
| 2019 | $180.42M | -6.93% |
| 2018 | $193.85M | 10.51% |
| 2017 | $175.41M | 69.99% |
| 2016 | $103.19M | -1.58% |
| 2015 | $104.84M | -43.47% |
| 2014 | $185.46M | -12.29% |
| 2013 | $211.43M | 3.94% |
| 2012 | $203.43M | 14.70% |
| 2011 | $177.35M | 51.03% |
| 2010 | $117.43M | 53.61% |
| 2009 | $76.45M | 48.40% |
| 2008 | $51.51M | 46.84% |
| 2007 | $35.08M | 0.00% |
Gewinn ähnlicher Unternehmen oder Konkurrenten
| Unternehmen | Gewinn | Gewinnunterschied | Land |
|---|---|---|---|
| $5.27B | 1,287.20% |
US
|
|
| $-3.09B | -911.82% |
US
|
|
| $-4.02B | -1,156.18% |
AU
|
|
| $3.01B | 690.44% |
BE
|
|
| $1.95B | 412.98% |
NL
|
